You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


iOmx doses first patient in pivotal phase 1 study

iOmx Therapeutics – a company developing targeted cancer immunotherapy treatments – has announced that the first individual has been dosed in its phase 1 clinical trial researching its OMX-0407 candidate.